SEP 16·SEC EDGARLow
Shen Ethan PhD purchased $49K of YDES
Shen Ethan PhD (CEO) purchased 12,700 shares of YD Bio Ltd (YDES) at $3.85 on 2026-09-14.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$YDES
YD Bio Ltd
Price · $YDESvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $YDES in the last 7 days.
Insider · 30dAll trades →
- Buys
- $129K 3 txs
- Sells
- — 0 txs
Shen Ethan PhD3× · $129K
10b5-1 share of filings0%
Top stories · $YDESMore →
SEP 10·SEC EDGAR
Shen Ethan PhD purchased $12K of YDES
Shen Ethan PhD (CEO) purchased 3,100 shares of YD Bio Ltd (YDES) at $3.93 on 2026-09-09.
SEP 8·SEC EDGAR
Shen Ethan PhD purchased $67K of YDES
Shen Ethan PhD (CEO) purchased 18,378 shares of YD Bio Ltd (YDES) at $3.67 on 2026-09-04.
YDES sentiment & insider activity
Recent YDES coverage spans insider activity, financial news and market movers.
In the last 30 days, YDES insiders filed 3 SEC Form 4 transactions — 3 purchases ($129K) and no sales. The most active reporter was Shen Ethan PhD, CEO, with 3 filings.
What's driving YDES
Small insider buy signals confidence but size is negligible for price.
Minor insider buy signals confidence but size is negligible relative to market cap.
Small insider buy unlikely to move price materially.
The earnings beat and profitability shift could trigger short‑term buying pressure, but the underlying profit is largely non‑cash, suggesting caution.
Revenue growth with worsening losses can sustain speculative interest while keeping downside risk elevated.
AlphAI scores every news story that mentions YDES with an AI model for sentiment and relevance, and aggregates insider trades from YD Bio Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $YDES
Score
Shen Ethan PhD purchased $49K of YDES
Shen Ethan PhD (CEO) purchased 12,700 shares of YD Bio Ltd (YDES) at $3.85 on 2026-09-14.
1 min readShen Ethan PhD purchased $12K of YDES
Shen Ethan PhD (CEO) purchased 3,100 shares of YD Bio Ltd (YDES) at $3.93 on 2026-09-09.
1 min readShen Ethan PhD purchased $67K of YDES
Shen Ethan PhD (CEO) purchased 18,378 shares of YD Bio Ltd (YDES) at $3.67 on 2026-09-04.
1 min readYD Bio Ltd (YDES): Financial results for H1 2026
YD Bio Ltd (YDES) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detec
2 min readAfter-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day
After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.
7 min readTop Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update
Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.
6 min read
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Limited (Nasdaq: YDES) said its affiliate EG BioMed US obtained out-of-state CLIA/CAP laboratory licenses in Rhode Island (clinical genetics, issued May 13, 2026) and Pennsylvania (clinical chemistry/hematology, issued June 9, 2026). The Bothell, Washington lab’s footprint now covers 46 states plus DC and Guam, supporting blood-based early cancer detection testing via its telehealth platform.
3 min readYD Bio launches telehealth platform for cancer detection By Investing.com
YD Bio Limited has announced the launch of its EG Telehealth Platform in collaboration with EG BioMed Co., Ltd., expanding cancer detection and monitoring services across 44 U.S. states, Washington, D.C., and Guam. This platform combines YD Bio's digital health infrastructure with EG BioMed's laboratory capabilities to screen for various cancers, including pancreatic, colorectal, liver, gastrointestinal, and breast cancers. The launch is a step towards scalable deployment, coinciding with YD Bio's ongoing plans to merge with EG BioMed and recent acquisitions to enhance its technological capabilities.
4 min readYD Bio (YDES) director files Form 3 with no share activity
YD Bio Ltd director Lee Jerry Yin-Chia has filed a Form 3 insider report for YDES, indicating no reported purchases, sales, or other insider transactions. The filing lists him as a director, with all transaction counts and share totals recorded as zero. This Form 3 filing confirms no insider trading activity from the specified director.
1 min readYD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities
Taipei, Taiwan, Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- YD Bio Limited ( "YD Bio" or the "Company" ) ( Nasdaq: YDES ) , a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG Biomed US Inc. ( ...
3 min read